Tag: platinum-resistant recurrent ovarian cancer

Image: PD 1. Combining bevacizumab with standard chemotherapy improved progression free survival and objective response rate in platinum-resistant ovarian cancer. 2. Adding bevacizumab did not significantly affect overall survival. Evidence rating level: 1 (Excellent) Study Rundown: Platinum-resistant recurrent ovarian cancer has an extremely poor prognosis, and is generally treated with single-agent chemotherapy with...